Cline Christopher R. 4

What Happened
Christopher R. Cline, Chief Financial Officer of Travere Therapeutics (TVTX), sold a total of 1,745 shares on February 4, 2026. The filing shows two sales: 1,635 shares at $32.14 each for $52,549, and 110 shares at $32.90 each for $3,619, for a combined proceeds of approximately $56,168. These were sales (transaction code S), reported in an open-market or private-sale format.

Key Details

• Transaction dates: February 4, 2026.
• Prices and amounts: 1,635 shares @ $32.14 ($52,549); 110 shares @ $32.90 ($3,619).
• Weighted average/price range: Footnote indicates a weighted average sale price of $32.14 and a price range of $31.645–$32.645; detailed per‑price breakdown available on request (SEC/issuer/holder).
• Footnotes: Sale made pursuant to a written 10b5‑1 trading plan adopted May 28, 2025; includes shares sold to cover tax obligations from RSU vesting.
• Shares owned after transaction: Not disclosed in the provided excerpt of the Form 4.
• Filing timeliness: Report filed on Feb 5, 2026 for a Feb 4, 2026 transaction (no late filing indication in this filing).

Context
Sales executed under a Rule 10b5‑1 plan and sales to cover tax withholding on vested restricted stock units are common and generally considered routine rather than a direct signal of management sentiment. For retail investors, purchases are often viewed as more informative than routine insider sales. This filing documents a straightforward sale of existing shares; it does not indicate any derivative exercise, gift, or new award.